Cardiome Pharma Corp (CRME) 9.76 $CRME
Coronary Artery Disease Therapeutics Pipeline Market H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Feb 05, 7:31AM CST
The report "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease). Coronary artery disease (Ischemic Heart Disease) is the most common type of heart disease. Coronary artery disease is the tightening or blockage of the coronary arteries. A severe adequate blockage may cause a heart attack. Coronary artery disease (Ischemic Heart Disease) is the foremost cause of death in US, UK and globally. Most ischaemic heart disease is caused by atherosclerosis. However there are a number of risk factors.
CRME: 9.76 (-0.14), GILD: 101.90 (+1.10), PSTI: 2.91 (+0.01), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), EGRX: 20.98 (+1.45), BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02)
Cardiome Pharma Has Returned 17.5% Since SmarTrend Recommendation (CRME)
Comtex SmarTrend(R) - Tue Feb 03, 9:34AM CST
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 13th, 2014 at $8.56. In approximately 3 months, Cardiome Pharma has returned 17.52% as of today's recent price of $10.06.
CRME: 9.76 (-0.14)
Cardiome Pharma Shares Up 20.9% Since SmarTrend's Buy Recommendation (CRME)
Comtex SmarTrend(R) - Tue Jan 27, 9:10AM CST
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 13th, 2014 at $8.56. In approximately 3 months, Cardiome Pharma has returned 20.91% as of today's recent price of $10.35.
CRME: 9.76 (-0.14)
Atrial Fibrillation Therapeutic Pipeline Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 3:31PM CST
The report "Atrial Fibrillation - Pipeline Review, H2 2015" provides comprehensive information on the therapeutic development for atrial fibrillation. Atrial fibrillation is the most ordinary type of arrhythmia. Atrial fibrillation is an unbalanced heartbeat that increases the threat of stroke and heart disease. Generally, the risk of developing atrial fibrillation increases with age and with other risk factors such as diabetes, high blood pressure, and underlying heart disease. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. The complete report is available at http://www.rnrmarketresearch.com/atrial-fibri...eport.html .
CRME: 9.76 (-0.14), GILD: 101.90 (+1.10), AZN: 69.96 (+0.20), BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02)
Uptrend Call Working As Cardiome Pharma Stock Rises 28.6% (CRME)
Comtex SmarTrend(R) - Tue Jan 20, 9:30AM CST
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 13th, 2014 at $8.56. In approximately 2 months, Cardiome Pharma has returned 28.62% as of today's recent price of $11.01.
CRME: 9.76 (-0.14)
Nasdaq stocks posting largest volume increases
AP - Thu Jan 15, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CRME: 9.76 (-0.14), SMSI: 1.60 (+0.07), DNBF: 22.59 (-0.41), PODD: 32.00 (-0.07), FLML: 14.15 (+0.15), QADB: 17.59 (+0.05), QADA: 20.36 (+0.14), WBKC: 23.75 (+0.03), COM.TO: 12.06 (-0.12), CMSB: 13.19 (+0.13), DWCH: 6.26 (-0.18)
Cardiome Pharma (CRME) in Focus: Stock Rises 5.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 7:44AM CST
Cardiome Pharma Corp. (CRME) was a big mover last session, as the company saw its shares rise a little over 5%
CRME: 9.76 (-0.14), PETX: 16.52 (-0.10)
Cardiome Pharma Shares Up 19.5% Since SmarTrend's Buy Recommendation (CRME)
Comtex SmarTrend(R) - Tue Jan 13, 1:08AM CST
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 13th, 2014 at $8.56. In approximately 2 months, Cardiome Pharma has returned 19.51% as of today's recent price of $10.23.
CRME: 9.76 (-0.14)
China Biotech Week In Review: Otsuka Buys Rights To ARIAD's Leukemia Drug
ChinaBio Today - at Seeking Alpha - Sun Dec 28, 11:30AM CST
Deals and Financings Otsuka Pharma (TYO: 4768) of Japan snagged marketing rights to Iclusig, a leukemia drug developed by ARIAD Pharmaceuticals (NASDAQ: ARIA ), for Japan, China and eight other Asian countries (see story ). Otsuka will pay $77.5...
CRME: 9.76 (-0.14), ARIA: 7.35 (+0.45)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), QLTI: 4.15 (unch), CTRX: 53.24 (+0.65), BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), TKMR: 21.45 (-0.22), NEPT: 1.83 (+0.06), BSX: 14.98 (+0.24), AGN: 229.49 (+1.87), CMRX: 40.16 (+0.08), ALNY: 95.54 (+1.67), SRPT: 12.76 (+0.11), SHPG: 239.82 (+6.11), NLNK: 38.84 (+1.51), SNY: 49.42 (+0.82), MSLI: 1.96 (+0.08), NVCN: 9.08 (-0.17), CRME: 9.76 (-0.14), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), NVDQ: 15.12 (+0.51), NVS: 102.20 (-0.17)
Cardiome Enters Development and Commercialization Agreement with Eddingpharm for BRINAVESS(TM) in China
CNW Group - Fri Dec 19, 7:00AM CST
NASDAQ: CRME TSX: COM
CRME: 9.76 (-0.14), COM.TO: 12.06 (-0.12)
Cardiome Enters Development and Commercialization Agreement with Eddingpharm for BRINAVESS™ in China
PR Newswire - Fri Dec 19, 7:00AM CST
NASDAQ: CRME TSX: COM
CRME: 9.76 (-0.14), COM.TO: 12.06 (-0.12)
Cardiome Enters Commercialization Agreement with Aspen for BRINAVESS® in South Africa
PR Newswire - Mon Nov 17, 7:30AM CST
NASDAQ: CRME TSX: COM
CRME: 9.76 (-0.14), COM.TO: 12.06 (-0.12)
Cardiome Pharma applies for BRINAVESS' reimbursement in Italy for atrial fibrillation
M2 - Mon Nov 10, 7:46AM CST
Pharmaceutical company Cardiome Pharma (NASDAQ:CRME)(TSX:COM) disclosed on Friday that it has submitted its BRINAVESS' reimbursement dossier to the Italian authorities in support of its market launch in the country.
CRME: 9.76 (-0.14), COM.TO: 12.06 (-0.12)
Cardiome Pharma's (CRME) CEO Bill Hunter on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 8:15PM CST
CRME: 9.76 (-0.14)
Cardiome Pharma misses by $0.13, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:22AM CST
CRME: 9.76 (-0.14)
Cardiome Reports Third Quarter 2014 Financial Results
CNW Group - Fri Nov 07, 6:00AM CST
NASDAQ: CRME TSX: COM
CRME: 9.76 (-0.14), COM.TO: 12.06 (-0.12)
Cardiome Submits BRINAVESS® Reimbursement Dossier to Italian Authorities to Support Market Access
PR Newswire - Fri Nov 07, 6:00AM CST
NASDAQ: CRME TSX: COM
CRME: 9.76 (-0.14), COM.TO: 12.06 (-0.12)
Coronary Artery Disease Therapeutics Pipeline Market H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Feb 05, 7:31AM CST
The report "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease). Coronary artery disease (Ischemic Heart Disease) is the most common type of heart disease. Coronary artery disease is the tightening or blockage of the coronary arteries. A severe adequate blockage may cause a heart attack. Coronary artery disease (Ischemic Heart Disease) is the foremost cause of death in US, UK and globally. Most ischaemic heart disease is caused by atherosclerosis. However there are a number of risk factors.
CRME: 9.76 (-0.14), GILD: 101.90 (+1.10), PSTI: 2.91 (+0.01), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), EGRX: 20.98 (+1.45), BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02)
Cardiome Pharma Has Returned 17.5% Since SmarTrend Recommendation (CRME)
Comtex SmarTrend(R) - Tue Feb 03, 9:34AM CST
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 13th, 2014 at $8.56. In approximately 3 months, Cardiome Pharma has returned 17.52% as of today's recent price of $10.06.
CRME: 9.76 (-0.14)
Cardiome Pharma Shares Up 20.9% Since SmarTrend's Buy Recommendation (CRME)
Comtex SmarTrend(R) - Tue Jan 27, 9:10AM CST
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 13th, 2014 at $8.56. In approximately 3 months, Cardiome Pharma has returned 20.91% as of today's recent price of $10.35.
CRME: 9.76 (-0.14)
Atrial Fibrillation Therapeutic Pipeline Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 3:31PM CST
The report "Atrial Fibrillation - Pipeline Review, H2 2015" provides comprehensive information on the therapeutic development for atrial fibrillation. Atrial fibrillation is the most ordinary type of arrhythmia. Atrial fibrillation is an unbalanced heartbeat that increases the threat of stroke and heart disease. Generally, the risk of developing atrial fibrillation increases with age and with other risk factors such as diabetes, high blood pressure, and underlying heart disease. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. The complete report is available at http://www.rnrmarketresearch.com/atrial-fibri...eport.html .
CRME: 9.76 (-0.14), GILD: 101.90 (+1.10), AZN: 69.96 (+0.20), BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02)
Uptrend Call Working As Cardiome Pharma Stock Rises 28.6% (CRME)
Comtex SmarTrend(R) - Tue Jan 20, 9:30AM CST
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 13th, 2014 at $8.56. In approximately 2 months, Cardiome Pharma has returned 28.62% as of today's recent price of $11.01.
CRME: 9.76 (-0.14)
Nasdaq stocks posting largest volume increases
AP - Thu Jan 15, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CRME: 9.76 (-0.14), SMSI: 1.60 (+0.07), DNBF: 22.59 (-0.41), PODD: 32.00 (-0.07), FLML: 14.15 (+0.15), QADB: 17.59 (+0.05), QADA: 20.36 (+0.14), WBKC: 23.75 (+0.03), COM.TO: 12.06 (-0.12), CMSB: 13.19 (+0.13), DWCH: 6.26 (-0.18)
Cardiome Pharma (CRME) in Focus: Stock Rises 5.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 7:44AM CST
Cardiome Pharma Corp. (CRME) was a big mover last session, as the company saw its shares rise a little over 5%
CRME: 9.76 (-0.14), PETX: 16.52 (-0.10)
Cardiome Pharma Shares Up 19.5% Since SmarTrend's Buy Recommendation (CRME)
Comtex SmarTrend(R) - Tue Jan 13, 1:08AM CST
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 13th, 2014 at $8.56. In approximately 2 months, Cardiome Pharma has returned 19.51% as of today's recent price of $10.23.
CRME: 9.76 (-0.14)
China Biotech Week In Review: Otsuka Buys Rights To ARIAD's Leukemia Drug
ChinaBio Today - at Seeking Alpha - Sun Dec 28, 11:30AM CST
Deals and Financings Otsuka Pharma (TYO: 4768) of Japan snagged marketing rights to Iclusig, a leukemia drug developed by ARIAD Pharmaceuticals (NASDAQ: ARIA ), for Japan, China and eight other Asian countries (see story ). Otsuka will pay $77.5...
CRME: 9.76 (-0.14), ARIA: 7.35 (+0.45)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), QLTI: 4.15 (unch), CTRX: 53.24 (+0.65), BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), TKMR: 21.45 (-0.22), NEPT: 1.83 (+0.06), BSX: 14.98 (+0.24), AGN: 229.49 (+1.87), CMRX: 40.16 (+0.08), ALNY: 95.54 (+1.67), SRPT: 12.76 (+0.11), SHPG: 239.82 (+6.11), NLNK: 38.84 (+1.51), SNY: 49.42 (+0.82), MSLI: 1.96 (+0.08), NVCN: 9.08 (-0.17), CRME: 9.76 (-0.14), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), NVDQ: 15.12 (+0.51), NVS: 102.20 (-0.17)
Cardiome Enters Development and Commercialization Agreement with Eddingpharm for BRINAVESS(TM) in China
CNW Group - Fri Dec 19, 7:00AM CST
NASDAQ: CRME TSX: COM
CRME: 9.76 (-0.14), COM.TO: 12.06 (-0.12)
Cardiome Enters Development and Commercialization Agreement with Eddingpharm for BRINAVESS™ in China
PR Newswire - Fri Dec 19, 7:00AM CST
NASDAQ: CRME TSX: COM
CRME: 9.76 (-0.14), COM.TO: 12.06 (-0.12)
Cardiome Enters Commercialization Agreement with Aspen for BRINAVESS® in South Africa
PR Newswire - Mon Nov 17, 7:30AM CST
NASDAQ: CRME TSX: COM
CRME: 9.76 (-0.14), COM.TO: 12.06 (-0.12)
Cardiome Pharma applies for BRINAVESS' reimbursement in Italy for atrial fibrillation
M2 - Mon Nov 10, 7:46AM CST
Pharmaceutical company Cardiome Pharma (NASDAQ:CRME)(TSX:COM) disclosed on Friday that it has submitted its BRINAVESS' reimbursement dossier to the Italian authorities in support of its market launch in the country.
CRME: 9.76 (-0.14), COM.TO: 12.06 (-0.12)
Cardiome Pharma's (CRME) CEO Bill Hunter on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 8:15PM CST
CRME: 9.76 (-0.14)
Cardiome Pharma misses by $0.13, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:22AM CST
CRME: 9.76 (-0.14)
Cardiome Reports Third Quarter 2014 Financial Results
CNW Group - Fri Nov 07, 6:00AM CST
NASDAQ: CRME TSX: COM
CRME: 9.76 (-0.14), COM.TO: 12.06 (-0.12)
Cardiome Submits BRINAVESS® Reimbursement Dossier to Italian Authorities to Support Market Access
PR Newswire - Fri Nov 07, 6:00AM CST
NASDAQ: CRME TSX: COM
CRME: 9.76 (-0.14), COM.TO: 12.06 (-0.12)
